The company is one of Wood's biggest biotech holdings.
News & Analysis: Vertex Pharmaceuticals
Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.
This biotech has likely reached its peak potential, for now.
Another clinical setback isn't sitting well with shareholders today.
It has a key advantage that should make a huge difference over the next 10 or more years.
The Food and Drug Administration has expanded eligibility for Trikafta to include amenable cystic fibrosis patients aged 6 to 11.
Two big biotech stocks and one smaller life sciences stock especially stand out.
The only thing similar between these two assets is the price.
At current levels, these two excellent companies are a bargain.
This biotech's growth has stalled. Should you give its stock a chance?